Limits...
Olfactory neuroblastoma: the long-term outcome and late toxicity of multimodal therapy including radiotherapy based on treatment planning using computed tomography.

Mori T, Onimaru R, Onodera S, Tsuchiya K, Yasuda K, Hatakeyama H, Kobayashi H, Terasaka S, Homma A, Shirato H - Radiat Oncol (2015)

Bottom Line: The 5-year overall survival (OS) and relapse-free survival (RFS) rates were estimated at 88% and 74%, respectively.Five patients with stage C disease had recurrence with the median time to recurrence of 59 months (range 7-115 months).Late adverse events equal to or above Grade 2 in CTCAE v4.03 were observed in three patients.

View Article: PubMed Central - PubMed

Affiliation: Department of Radiation Oncology, Hokkaido University Hospital, Sapporo, Japan. tamori-tym@umin.ac.jp.

ABSTRACT

Background: Olfactory neuroblastoma (ONB) is a rare tumor originating from olfactory epithelium. Here we retrospectively analyzed the long-term treatment outcomes and toxicity of radiotherapy for ONB patients for whom computed tomography (CT) and three-dimensional treatment planning was conducted to reappraise the role of radiotherapy in the light of recent advanced technology and chemotherapy.

Methods: Seventeen patients with ONB treated between July 1992 and June 2013 were included. Three patients were Kadish stage B and 14 were stage C. All patients were treated with radiotherapy with or without surgery or chemotherapy. The radiation dose was distributed from 50 Gy to 66 Gy except for one patient who received 40 Gy preoperatively.

Results: The median follow-up time was 95 months (range 8-173 months). The 5-year overall survival (OS) and relapse-free survival (RFS) rates were estimated at 88% and 74%, respectively. Five patients with stage C disease had recurrence with the median time to recurrence of 59 months (range 7-115 months). Late adverse events equal to or above Grade 2 in CTCAE v4.03 were observed in three patients.

Conclusion: Multimodal therapy including radiotherapy with precise treatment planning based on CT simulation achieved an excellent local control rate with acceptable toxicity and reasonable overall survival for patients with ONB.

No MeSH data available.


Related in: MedlinePlus

Axial view of follow-up MRI 10 years after radiotherapy (patient 1). Retinopathy of the left eye was observed.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4403781&req=5

Fig5: Axial view of follow-up MRI 10 years after radiotherapy (patient 1). Retinopathy of the left eye was observed.

Mentions: Late adverse effects equal to or above Grade 2 in CTCAE v4.03 were observed in all of these patients; two patients showed Grade 2 hypopituitarism such as hypothyroidism or adrenal insufficiency at 75 and 103 months after the completion of radiotherapy. One of these patients was prescribed 66Gy in 33 fractions with a stereotactic boost to the ethmoid sinus with 10 Gy in four fractions and to the sphenoid bone with 28 Gy in four fractions (patient 13). The other patient was prescribed 65 Gy in 26 fractions (patient 1), and the dose to the pituitary sinus was estimated as 52 to 62 Gy in 26 fractions from the dose distribution. This patient also suffered from Grade 4 glaucoma, retinopathy, and vitreous hemorrhage and needed ophthalmological intervention. The maximum dose to the eye was estimated as 58 Gy in 26 fractions from the dose distribution (Figure 4). This patient treated with X-ray and electron beam, and the radiation injury occurred in the area that matched the field of X-ray and electron beam. A follow-up MRI and a fundus photograph of the patient’s left eye 10 years after the radiotherapy are shown in Figure 5 and Figure 6.Figure 4


Olfactory neuroblastoma: the long-term outcome and late toxicity of multimodal therapy including radiotherapy based on treatment planning using computed tomography.

Mori T, Onimaru R, Onodera S, Tsuchiya K, Yasuda K, Hatakeyama H, Kobayashi H, Terasaka S, Homma A, Shirato H - Radiat Oncol (2015)

Axial view of follow-up MRI 10 years after radiotherapy (patient 1). Retinopathy of the left eye was observed.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4403781&req=5

Fig5: Axial view of follow-up MRI 10 years after radiotherapy (patient 1). Retinopathy of the left eye was observed.
Mentions: Late adverse effects equal to or above Grade 2 in CTCAE v4.03 were observed in all of these patients; two patients showed Grade 2 hypopituitarism such as hypothyroidism or adrenal insufficiency at 75 and 103 months after the completion of radiotherapy. One of these patients was prescribed 66Gy in 33 fractions with a stereotactic boost to the ethmoid sinus with 10 Gy in four fractions and to the sphenoid bone with 28 Gy in four fractions (patient 13). The other patient was prescribed 65 Gy in 26 fractions (patient 1), and the dose to the pituitary sinus was estimated as 52 to 62 Gy in 26 fractions from the dose distribution. This patient also suffered from Grade 4 glaucoma, retinopathy, and vitreous hemorrhage and needed ophthalmological intervention. The maximum dose to the eye was estimated as 58 Gy in 26 fractions from the dose distribution (Figure 4). This patient treated with X-ray and electron beam, and the radiation injury occurred in the area that matched the field of X-ray and electron beam. A follow-up MRI and a fundus photograph of the patient’s left eye 10 years after the radiotherapy are shown in Figure 5 and Figure 6.Figure 4

Bottom Line: The 5-year overall survival (OS) and relapse-free survival (RFS) rates were estimated at 88% and 74%, respectively.Five patients with stage C disease had recurrence with the median time to recurrence of 59 months (range 7-115 months).Late adverse events equal to or above Grade 2 in CTCAE v4.03 were observed in three patients.

View Article: PubMed Central - PubMed

Affiliation: Department of Radiation Oncology, Hokkaido University Hospital, Sapporo, Japan. tamori-tym@umin.ac.jp.

ABSTRACT

Background: Olfactory neuroblastoma (ONB) is a rare tumor originating from olfactory epithelium. Here we retrospectively analyzed the long-term treatment outcomes and toxicity of radiotherapy for ONB patients for whom computed tomography (CT) and three-dimensional treatment planning was conducted to reappraise the role of radiotherapy in the light of recent advanced technology and chemotherapy.

Methods: Seventeen patients with ONB treated between July 1992 and June 2013 were included. Three patients were Kadish stage B and 14 were stage C. All patients were treated with radiotherapy with or without surgery or chemotherapy. The radiation dose was distributed from 50 Gy to 66 Gy except for one patient who received 40 Gy preoperatively.

Results: The median follow-up time was 95 months (range 8-173 months). The 5-year overall survival (OS) and relapse-free survival (RFS) rates were estimated at 88% and 74%, respectively. Five patients with stage C disease had recurrence with the median time to recurrence of 59 months (range 7-115 months). Late adverse events equal to or above Grade 2 in CTCAE v4.03 were observed in three patients.

Conclusion: Multimodal therapy including radiotherapy with precise treatment planning based on CT simulation achieved an excellent local control rate with acceptable toxicity and reasonable overall survival for patients with ONB.

No MeSH data available.


Related in: MedlinePlus